QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 7 作者:  Xia, Zong-jun;  Ji, Yin-chun;  Sun, De-qiao;  Peng, Xia;  Gao, Ying-lei 收藏  |  浏览/下载：75/0  |  提交时间：2020/12/21 ROS1 kinase  ROS1 inhibitor  SAF-189s  lorlatinib  crizotinib resistance  G2032R mutant  NSCLC   Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments: A MD Simulation and NMR Study 期刊论文 ACS OMEGA, 2019, 卷号: 4, 期号: 26, 页码: 22245-22250 作者:  Peng, Cheng;  Atilaw, Yoseph;  Wang, Jinan;  Xu, Zhijian;  Poongavanam, Vasanthanathan 收藏  |  浏览/下载：23/0  |  提交时间：2020/07/01 Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry 期刊论文 2019, 卷号: 2019, 页码: 7574369 作者:  Chen, Wei;  Shi, Yafei;  Qi, Shuya;  Zhou, Haiyan;  Li, Chunyu 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report 期刊论文 BMC PULMONARY MEDICINE, 2018, 卷号: 18 作者:  Dong, Liang;  Xia, Jingwen;  Zhang, Jing;  Zhang, Yuanyuan;  Zhu, Ning 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Lung adenocarcinoma  ROS1 rearrangement  Pemetrexed  Crizotinib  Lorlatinib   Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report 期刊论文 BMC PULMONARY MEDICINE, 2018, 卷号: Vol.18 作者:  Dong, L;  Xia, JW;  Zhang, J;  Zhang, YY;  Zhu, N 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/26 Lung  adenocarcinoma  ROS1  rearrangement  Pemetrexed  Crizotinib  Lorlatinib   Drug resistance in ALK-positiveNon-small cell lungcancer patients 期刊论文 SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2017, 卷号: 64 作者:  Qian, Mengjia;  Zhu, Bijun;  Wang, Xiangdong;  Liebman, Michael 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 ALK  Point mutation  Crizotinib  Ceritinib  Alectinib  Lorlatinib   L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites. 期刊论文 Int J Mol Sci, 2017, 卷号: Vol.18 No.3 作者:  Li J;  Sun R;  Wu Y;  Song M;  Yang Q 收藏  |  浏览/下载：3/0  |  提交时间：2019/03/01 ALK  drug  resistance  lorlatinib  point  mutation  resensitization